Extrusion 3D‐printed tricalcium phosphate‐polycaprolactone biocomposites for quercetin‐KCl delivery in bone tissue engineering

Abstract

AbstractCritical‐sized bone defects pose a significant challenge in advanced healthcare due to limited bone tissue regenerative capacity. The complex interplay of numerous overlapping variables hinders the development of multifunctional biocomposites. Phytochemicals show promise in promoting bone growth, but their dose‐dependent nature and physicochemical properties halt clinical use. To develop a comprehensive solution, a 3D‐printed (3DP) extrusion‐based tricalcium phosphate‐polycaprolactone (TCP‐PCL) scaffold is augmented with quercetin and potassium chloride (KCl). This composite material demonstrates a compressive strength of 30 MPa showing promising stability for low load‐bearing applications. Quercetin release from the scaffold follows a biphasic pattern that persists for up to 28 days, driven via diffusion‐mediated kinetics. The incorporation of KCl allows for tunable degradation rates of scaffolds and prevents the initial rapid release. Functionalization of scaffolds facilitates the attachment and proliferation of human fetal osteoblasts (hfOB), resulting in a 2.1‐fold increase in cell viability. Treated scaffolds exhibit a 3‐fold reduction in osteosarcoma (MG‐63) cell viability as compared to untreated substrates. Ruptured cell morphology and decreased mitochondrial membrane potential indicate the antitumorigenic potential. Scaffolds loaded with quercetin and quercetin‐KCl (Q‐KCl) demonstrate 76% and 89% reduction in bacterial colonies of Staphylococcus aureus, respectively. This study provides valuable insights as a promising strategy for bone tissue engineering (BTE) in orthopedic repair.